Search

Your search keyword '"Grand'Maison, F"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Grand'Maison, F" Remove constraint Author: "Grand'Maison, F" Topic business Remove constraint Topic: business
32 results on '"Grand'Maison, F"'

Search Results

1. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

2. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

3. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

4. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

5. 250 mu g or 500 mu g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

6. Health-related quality of life in multiple sclerosis: Effects of natalizumab

7. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry

8. Determinants of therapeutic lag in multiple sclerosis

9. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

10. Timing of high-efficacy therapy for multiple sclerosis:a retrospective observational cohort study

11. Early clinical markers of aggressive multiple sclerosis

12. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

13. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

14. Risk of secondary progressive multiple sclerosis: A longitudinal study

15. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

16. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

17. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

18. BREMSO: a simple score to predict early the natural course of multiple sclerosis

19. Risk of relapse phenotype recurrence in multiple sclerosis

20. Fingolimod after natalizumab and the risk of short-term relapse

21. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

22. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

23. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

24. Predictors of disability worsening in clinically isolated syndrome

25. Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

26. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

27. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

28. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

29. Fluctuations of MS births and UV-light exposure

30. Increasing age at disability milestones among MS patients in the MSBase Registry

31. Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome

32. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Catalog

Books, media, physical & digital resources